Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12. The firm cites the company ...

Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet ...

Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...

Retatrutide mimics the effects of naturally occurring gut hormones to improve metabolic health. Stimulating insulin release ...

Yes. So Tyler, I'm happy to be here, everyone. Good to see you and very happy to talk about EYLEA HD. So we absolutely believe that our EYLEA HD has the potential to be the new standard-of-care in ...

Earlier this month, the South Korean biosimilar maker secured approval for three other drugs from Europe: Eydenzelt, referencing blockbuster eye disease treatment Eylea; Stoboclo and Osenvelt.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Regeneron paid credit card fees to distributors on the condition that distributors did not ...

Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CEST The issuer is solely responsible for ...

The other three — Tofidence™ and Tyenne® for Actemra® (tocilizumab) and Pavblu™ for Eylea® (aflibercept) — were the first commercially available biosimilars for their respective ...

FYB203 (aflibercept) approved in the UK for the treatment of neovascular age-related macular degeneration (nAMD) and several other severe retinal diseases UK market authorization follows successful ...

Regeneron paid credit card fees to distributors on the condition that those distributors did not charge purchasers of its Eylea drug more to use a credit card. The Company's payments subsidized ...

For example, Regeneron's (REGN) Eylea and Eylea HD, as well as Genentech's Lucentis and Vabysmo, could be considered the “previous generation” of anti-VEGF drugs. Currently, the next step for ...